We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Ascends While Market Falls: Some Facts to Note
Read MoreHide Full Article
The most recent trading session ended with Pfizer (PFE - Free Report) standing at $28.39, reflecting a +0.32% shift from the previouse trading day's closing. This change outpaced the S&P 500's 0.16% loss on the day. Elsewhere, the Dow saw an upswing of 0.09%, while the tech-heavy Nasdaq depreciated by 0.3%.
Heading into today, shares of the drugmaker had lost 3.48% over the past month, lagging the Medical sector's gain of 4.7% and the S&P 500's gain of 3.64% in that time.
Investors will be eagerly watching for the performance of Pfizer in its upcoming earnings disclosure. On that day, Pfizer is projected to report earnings of $0.63 per share, which would represent year-over-year growth of 470.59%. Our most recent consensus estimate is calling for quarterly revenue of $15.46 billion, up 16.82% from the year-ago period.
PFE's full-year Zacks Consensus Estimates are calling for earnings of $2.62 per share and revenue of $61.49 billion. These results would represent year-over-year changes of +42.39% and +5.12%, respectively.
Investors should also take note of any recent adjustments to analyst estimates for Pfizer. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.42% downward. At present, Pfizer boasts a Zacks Rank of #3 (Hold).
Digging into valuation, Pfizer currently has a Forward P/E ratio of 10.78. This represents a discount compared to its industry's average Forward P/E of 16.26.
It is also worth noting that PFE currently has a PEG ratio of 1.01. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As the market closed yesterday, the Large Cap Pharmaceuticals industry was having an average PEG ratio of 1.68.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 61, finds itself in the top 25% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pfizer (PFE) Ascends While Market Falls: Some Facts to Note
The most recent trading session ended with Pfizer (PFE - Free Report) standing at $28.39, reflecting a +0.32% shift from the previouse trading day's closing. This change outpaced the S&P 500's 0.16% loss on the day. Elsewhere, the Dow saw an upswing of 0.09%, while the tech-heavy Nasdaq depreciated by 0.3%.
Heading into today, shares of the drugmaker had lost 3.48% over the past month, lagging the Medical sector's gain of 4.7% and the S&P 500's gain of 3.64% in that time.
Investors will be eagerly watching for the performance of Pfizer in its upcoming earnings disclosure. On that day, Pfizer is projected to report earnings of $0.63 per share, which would represent year-over-year growth of 470.59%. Our most recent consensus estimate is calling for quarterly revenue of $15.46 billion, up 16.82% from the year-ago period.
PFE's full-year Zacks Consensus Estimates are calling for earnings of $2.62 per share and revenue of $61.49 billion. These results would represent year-over-year changes of +42.39% and +5.12%, respectively.
Investors should also take note of any recent adjustments to analyst estimates for Pfizer. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.42% downward. At present, Pfizer boasts a Zacks Rank of #3 (Hold).
Digging into valuation, Pfizer currently has a Forward P/E ratio of 10.78. This represents a discount compared to its industry's average Forward P/E of 16.26.
It is also worth noting that PFE currently has a PEG ratio of 1.01. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As the market closed yesterday, the Large Cap Pharmaceuticals industry was having an average PEG ratio of 1.68.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 61, finds itself in the top 25% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.